Turan A, Kaya G, Karamanlioglu B, Pamukçu Z, Apfel C C
Department of Anaesthesiology, Trakya University, Turkey.
Br J Anaesth. 2006 Feb;96(2):242-6. doi: 10.1093/bja/aei294. Epub 2005 Dec 16.
Gabapentin has been used successfully as a non-opioid analgesic adjuvant for postoperative pain management. We hypothesized that gabapentin might be a useful adjuvant for postoperative analgesia provided with patient-controlled epidural analgesia (PCEA).
Forty patients undergoing lower extremity surgery procedures were randomly assigned to receive (i) placebo capsules (control) or (ii) gabapentin (1.2 g day(-1)) before and for 2 days after surgery. Anaesthetic technique was standardized. Postoperative assessments included verbal rating scale scoring for pain and sedation, PCEA usage, quality of recovery assessment, times of GI function recovery, and patient satisfaction scoring for pain management.
Pain scores at 1, 4, 8, 12, and 16 h (P<0.001), PCEA bolus requirements (n) at 24 [21 (3), 14 (2)], 48 [15 (4), 10 (3)] and 72 [8 (5), 2 (3)] (P<0.05) and paracetamol (mg) consumption [700 (523), 350 (400)]; P<0.05), were significantly lower in the gabapentin-treated patients than in the control group. Patient satisfaction with postoperative pain management at 24 h was better in gabapentin-treated patients [85.5 (7.5), 66.5 (15)]; P<0.001). Gabapentin-treated patients had less motor block when compared with control group. Times of return of bowel function, hospitalization, and resumption of dietary intake were similar in the groups. However, the incidence of dizziness was higher in the gabapentin group (35% vs 5%; P<0.05).
Oral gabapentin (1.2 g day(-1)) as an adjunct to epidural analgesia decreased pain and analgesic consumption. Despite an increased incidence of dizziness it also increased patient satisfaction.
加巴喷丁已成功用作术后疼痛管理的非阿片类镇痛辅助药物。我们推测加巴喷丁可能是患者自控硬膜外镇痛(PCEA)术后镇痛的有用辅助药物。
40例行下肢手术的患者被随机分配接受(i)安慰剂胶囊(对照组)或(ii)加巴喷丁(1.2克/天),术前及术后2天使用。麻醉技术标准化。术后评估包括疼痛和镇静的视觉模拟评分、PCEA使用情况、恢复质量评估、胃肠功能恢复时间以及患者对疼痛管理的满意度评分。
加巴喷丁治疗组患者在术后1、4、8、12和16小时的疼痛评分(P<0.001)、24小时[21(3),14(2)]、48小时[15(4),10(3)]和72小时[8(5),2(3)]的PCEA推注需求量(n)(P<0.05)以及对乙酰氨基酚消耗量[700(523),350(400)];P<0.05)均显著低于对照组。加巴喷丁治疗组患者术后24小时对疼痛管理的满意度更高[85.5(7.5),66.5(15)];P<0.001)。与对照组相比,加巴喷丁治疗组患者的运动阻滞较轻。两组患者的肠功能恢复时间、住院时间和饮食恢复时间相似。然而,加巴喷丁组头晕的发生率更高(35%对5%;P<0.05)。
口服加巴喷丁(1.2克/天)作为硬膜外镇痛的辅助药物可减轻疼痛并减少镇痛药物的消耗。尽管头晕发生率增加,但它也提高了患者满意度。